May 10, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: |
Dorrie Yale | |||||
| Re: |
ARCA biopharma, Inc. Registration Statement on Form S-3 File No. 333-217459 | |||||
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on May 8, 2017, in which we requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-217459) to Wednesday, May 10, 2017, at 4:00 p.m., Eastern Daylight Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date thereof.
| Very truly yours,
ARCA biopharma, Inc. | ||
| By: | /s/ Brian L. Selby | |
| Brian L. Selby Vice President, Finance | ||
cc: Brent Fassett, Cooley LLP